Personal information

No personal information available

Activities

Collapse all

Works (27)

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study

JHEP Reports
2023-10 | Journal article
DOI: 10.1016/j.jhepr.2023.100851
Contributors: Edmond Atallah; Sarah J. Welsh; Brent O’Carrigan; Ana Oshaughnessy; Igboin Dolapo; Andrew S. Kerr; Joanna Kucharczak; Colin Y.C. Lee; Colin Crooks; Amy Hicks et al.
Source: check_circle
Crossref

Data from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532443
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Data from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532443.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Data from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487055
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Data from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487055.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487052
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487052.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487049.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487043
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487040
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487049
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487046.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487043.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487040.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487046
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487031.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487034.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487034
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487037
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487037.v1
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487031
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review

Kidney Cancer
2022-12-29 | Journal article
DOI: 10.3233/KCA-220012
Contributors: James O. Jones; William H. J. Ince; Sarah J. Welsh; Grant D. Stewart
Source: check_circle
Crossref

Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib

BJU International
2022-08 | Journal article
DOI: 10.1111/bju.15600
Contributors: Sarah J. Welsh; Nicola Thompson; Anne Warren; Andrew N. Priest; Tristan Barrett; Stephan Ursprung; Ferdia A. Gallagher; Fulvio Zaccagna; Grant D. Stewart; Kate M. Fife et al.
Source: check_circle
Crossref

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

Clinical Cancer Research
2022-07-15 | Journal article
DOI: 10.1158/1078-0432.CCR-21-4115
Contributors: Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour et al.
Source: check_circle
Crossref

Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials

British Journal of Cancer
2022-02-01 | Journal article
DOI: 10.1038/s41416-021-01613-5
Contributors: Helen Mossop; Michael J. Grayling; Ferdia A. Gallagher; Sarah J. Welsh; Grant D. Stewart; James M. S. Wason
Source: check_circle
Crossref

Hyperpolarized <sup>13</sup>C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma&mdash;A Proof of Principle Study

Cancers
2022-01 | Journal article | Author
DOI: 10.3390/cancers14020335
Contributors: Stephan Ursprung; Ramona Woitek; Mary A. McLean; Andrew Nicholas Priest; Mireia Crispin-Ortuzar; Cara R. Brodie; Andrew Gill; Marcel Gehrung; Lucian Beer; Antony C. P. Riddick et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

Biology
2020-04 | Journal article | Author
DOI: 10.3390/biology9040074
Contributors: Rafia S. Al-Lamki; Nicholas J. Hudson; John R. Bradley; ANNE WARREN; Tim Eisen; Sarah Welsh; Antony C. P. Riddick; Fiach C. O’Mahony; Arran Turnbull; Thomas Powles et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Peer review (1 review for 1 publication/grant)

Review activity for British journal of cancer. (1)
How many people are using ORCID?